



Supplementary Materials: The Impact of *BRAF* Mutation Status on Survival Outcomes and Treatment Patterns among Metastatic Colorectal Cancer Patients in Alberta, Canada


R. Liam Sutherland, Devon J. Boyne, Darren R. Brenner and Winson Y. Cheung



(A)



(B)



(C)

Figure S1: Kaplan-Meier curves depicting survival from time of initiation of second-line therapy to all-cause death. (A) Overall survival. (B) Stratified by *BRAF* status. (C) Stratified by second-line therapy regimen.

Table S1. Treatment regimens for third- and fourth-line therapy among metastatic colorectal cancer patients.

Treatment Group	Overall	Mutant	Wild-Type	Not Tested	p
	n = 488	n = 42	n = 325	n = 121	
Third-line (%)	96 (49.5)	<10	87 (53.4)	<10	0.892
Capecitabine	<10	<10	<10	<10	
CAPOX or FOLFOX	21 (21.9)	<10	20 (23.0)	<10	
CAPOX or FOLFOX + MAB	<10	<10	<10	<10	
FOLFIRI	12 (12.5)	<10	11 (12.6)	<10	
FOLFIRI + MAB	11 (11.5)	<10	11 (12.6)	<10	
Panitumumab	24 (25.0)	<10	22 (25.3)	<10	0.92
Other	24 (25.0)	<10	19 (21.8)	<10	
Fourth-line (%)	30 (31.2)	<10	28 (32.2)	<10	
CAPOX or FOLFOX	<10	<10	<10	<10	
CAPOX or FOLFOX + MAB	<10	<10	<10	<10	
FOLFIRI	<10	<10	<10	<10	
FOLFIRI + MAB	<10	<10	<10	<10	
Other	12 (40.0)	<10	10 (35.7)	<10	

<10: data censored due to small cell size.

CAPOX = Capecitabine (Xeloda) and Oxaliplatin (Eloxatin); FOLFIRI = Fluorouracil (5-Fluorouracil, Efudex, Fluoroplex) and Irinotecan and Leucovorin Calcium; FOLFOX = Fluorouracil (5-Fluorouracil, Efudex, Fluoroplex) and Leucovorin Calcium and Oxaliplatin (Eloxatin); MAB = monoclonal antibody.

Table S2. Survival analyses from initiation of second-line therapy to all-cause death.

Strata	Median survival in months (95% CI)	1 year survival probability (95% CI)	2 year survival probability (95% CI)
Overall	11.24 (9.36-14.75)	0.48 (0.40-0.56)	0.17 (0.12-0.26)
<i>BRAF</i> Status			
Wild type	12.16 (9.43-15.38)	0.50 (0.42-0.60)	0.16 (0.11-0.26)
Mutant	4.17 (3.48-18.46)	0.21 (0.08-0.58)	0.07 (0.01-0.47)
Not-tested	NA	0.51 (0.28-0.94)	0.51 (0.28-0.94)
Treatment Group			
Capecitabine	16.56 (11.17-NA)	0.68 (0.47-1.00)	0.31 (0.12-0.76)
CAPOX or FOLFOX	11.38 (9.36-18.46)	0.45 (0.33-0.62)	0.20 (0.10-0.38)
FOLFIRI	8.44 (5.58-15.11)	0.38 (0.25-0.59)	0.14 (0.06-0.37)
FOLFIRI + MAB	18.00 (6.96-26.48)	0.62 (0.45-0.87)	0.31 (0.15-0.63)
Other	8.64 (5.29--18.30)	0.40 (0.26-0.62)	0.10 (0.03-0.34)

BRAF = v-raf murine sarcoma viral oncogene homolog B1; CI = confidence interval; CAPOX = Capecitabine (Xeloda) and Oxaliplatin (Eloxatin); FOLFIRI = Fluorouracil (5-Fluorouracil, Efudex, Fluoroplex) and Irinotecan and Leucovorin Calcium; FOLFOX = Fluorouracil (5-Fluorouracil, Efudex, Fluoroplex) and Leucovorin Calcium and Oxaliplatin (Eloxatin); MAB = monoclonal antibody; NA = not available.

Table S3. Survival analyses from initiation of second-line therapy to cancer-specific death.

Strata	Median survival in months (95% CI)	1 year survival probability (95% CI)	2 year survival probability (95% CI)
Overall	12.35 (10.35-16.56)	0.52 (0.44-0.61)	0.22 (0.15-0.31)
<i>BRAF</i> Status			
Wild type	12.81 (10.45-16.79)	0.54 (0.46-0.63)	0.20 (0.14-0.31)
Mutant	4.37 (3.58-NA)	0.24 (0.09-0.63)	0.12 (0.02-0.65)
Not-tested	NA	0.61 (0.38-1.00)	0.61 (0.38-1.00)
Treatment Group			
Capecitabine	15.56 (11.17-NA)	0.68 (0.47-1.00)	0.31 (0.12-0.76)
CAPOX or FOLFOX	12.35 (9.36-20.73)	0.52 (0.40-0.69)	0.24 (0.13-0.46)
FOLFIRI	8.61 (7.13-15.41)	0.42 (0.28-0.62)	0.16 (0.06-0.40)
FOLFIRI + MAB	21.49 (15.51-NA)	0.70 (0.53-0.93)	0.41 (0.22-0.76)
Other	8.64 (6.54-20.20)	0.42 (0.27-0.64)	0.15 (0.05-0.48)

BRAF = v-raf murine sarcoma viral oncogene homolog B1; CI = confidence interval; CAPOX = Capecitabine (Xeloda) and Oxaliplatin (Eloxatin); FOLFIRI = Fluorouracil (5-Fluorouracil, Efudex, Fluoroplex) and Irinotecan and Leucovorin Calcium; FOLFOX = Fluorouracil (5-Fluorouracil, Efudex, Fluoroplex) and Leucovorin Calcium and Oxaliplatin (Eloxatin); MAB = monoclonal antibody; NA = not available.